Early trial tests new drug timing for Tough-to-Treat blood cancer
NCT ID NCT02537613
Summary
This early-stage study is testing whether two already-approved leukemia drugs—ibrutinib and obinutuzumab—are safe when given together and in what order. It involves 54 adults whose chronic lymphocytic leukemia has returned or stopped responding to previous treatments. The main goal is to find the safest way to combine these drugs, not to cure the disease.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC LYMPHOCYTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Dana Farber Cancer Institute
Boston, Massachusetts, 02215, United States
-
Duke University Medical Center
Durham, North Carolina, 27710, United States
-
Massachusetts General Hospital
Boston, Massachusetts, 02114, United States
-
University of Rochester Wilmot Cancer Inst.
Rochester, New York, 14642, United States
Conditions
Explore the condition pages connected to this study.